Back to Search
WILLIAM BLALOCK, MD
MD
Cardiovascular Disease Physician
NPI: 1740254820IndividualAccepts Medicare
Specialties, Licenses & Credentials
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
21693(TN)
CMS Specialties
PrimaryCARDIOVASCULAR DISEASE (CARDIOLOGY)
Education
WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE
Class of 1988
Research & Publications (20)
A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis-associated extra type III domain B.
PMID 19479996·Int J Cancer·2009
7-preclinical
Use of uteroglobin for the engineering of polyvalent, polyspecific fusion proteins.
PMID 19632988·J Biol Chem·2009
7-preclinical
PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation.
PMID 19507191·J Cell Physiol·2009
8-other
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes.
PMID 17625605·Leukemia·2008
5-case
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia.
PMID 18577685·Mol Pharmacol·2008
8-other
PKR is activated in MDS patients and its subcellular localization depends on disease severity.
PMID 18496558·Leukemia·2008
8-other
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
PMID 17691943·Curr Med Chem·2007
6-review
RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy, and viral infection.
PMID 16861340·Blood·2006
7-preclinical
Serine 18 phosphorylation of RAX, the PKR activator, is required for PKR activation and consequent translation inhibition.
PMID 15299031·J Biol Chem·2004
7-preclinical
Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells.
PMID 15004527·Cell Cycle·2004
7-preclinical
Elucidation of signal transduction pathways by transfection of cells with modified oncogenes.
PMID 12616723·Methods Mol Biol·2003
8-other
Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation.
PMID 12970777·Leukemia·2003
4-observational
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.
PMID 12835716·Leukemia·2003
6-review
Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
PMID 12764369·Leukemia·2003
7-preclinical
Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells.
PMID 12717425·Oncogene·2003
7-preclinical
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.
PMID 12646949·Leukemia·2003
6-review
Elucidation of signal transduction pathways by retroviral infection of cells with modified oncogenes.
PMID 12616724·Methods Mol Biol·2003
8-other
Fibroblastic, hematopoietic, and hormone responsive epithelial cell lines and culture conditions for elucidation of signal transduction and drug resistance pathways by gene transfer.
PMID 12616722·Methods Mol Biol·2003
6-review
Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review).
PMID 12579299·Int J Oncol·2003
6-review
Enhanced ability of the progenipoietin-1 to suppress apoptosis in human hematopoietic cells.
PMID 12239583·Int J Mol Med·2002
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1614 GUNBARREL RD, SUITE 101
CHATTANOOGA, TN 37421 - Phone
- (423) 553-7600
Quick Facts
- NPI
- 1740254820
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 38
- Publications
- 20
Are you this provider?
Claim Your Profile